Research programme: Burkholderia cepacia infections - Demegen
Latest Information Update: 25 Feb 2008
At a glance
- Originator Demegen
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Burkholderia cepacia infections
Most Recent Events
- 27 Jun 2003 Suspended - Preclinical for Burkholderia cepacia infections in USA (unspecified route)
- 07 Nov 2001 Preclinical development for Burkholderia cepacia infections in USA (Unknown route)